What Is KLOW Protocol?
KLOW is a research peptide combination that builds upon the GLOW protocol by adding KPV for enhanced anti-inflammatory effects. Vendors typically sell KLOW as a single vial combining GHK-Cu, TB-500, BPC-157 and KPV in a 5:1:1:1 ratio by weight. While individual components have varying levels of research support, no clinical trials have examined this specific four-peptide combination. The protocol remains investigational with theoretical benefits based on complementary mechanisms.
Mechanism of Action
Each peptide contributes different mechanisms: GHK-Cu modulates genes, TB-500 enhances cell migration, BPC-157 upregulates growth factors, KPV inhibits NF-κB
Key Benefits
Theoretical synergistic effects from four peptides - tissue repair, anti-inflammation, cellular regeneration
Quick Reference
Member reference tables summarize the compound's research parameters.
Research Indications
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below), not a personal dosing recommendation.
This member section describes parameters reported in the research literature.
Peptide Interactions
This member section summarizes reported compound interactions and evidence limitations.
Reported Research Time Points
This member section summarizes reported research time points.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
This member section discusses research safety considerations and uncertainties.
Quality Indicators
Research Citations
- No Published Studies on KLOW Combination
No clinical trials | No safety studies | No peer-reviewed research - Two-Peptide Combinations Only (Various)
Limited research | BPC-157 + TB-500 | Animal models